Institutional & Family Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Institutional & Family Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13	Closed	-$2K	–	885
2019 Q2	$2K	Hold	13	–	–	﹤0.01%	743
2019 Q1	$2K	Hold	13	–	–	﹤0.01%	737
2018 Q4	$1K	Sell	13 -8	-38%	-$1K	﹤0.01%	789
2018 Q3	$3K	Hold	21	–	–	﹤0.01%	699
2018 Q2	$3K	Sell	21 -8	-28%	-$754	﹤0.01%	685
2018 Q1	$2K	Buy	+29	New	+$1.93K	﹤0.01%	732

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Institutional & Family Asset Management's SRPT Position: Q3 2019 in Review

Institutional & Family Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 13 shares — an estimated $2K sold.

Institutional & Family Asset Management first reported a position in SRPT in Q1 2018 and held it in 6 quarters. The position peaked at $3K in Q3 2018. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

Institutional & Family Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
Institutional & Family Asset Management sold 13 Sarepta Therapeutics shares in Q3 2019, an estimated $2K.
Institutional & Family Asset Management first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 6 quarters.
Institutional & Family Asset Management's Sarepta Therapeutics position peaked at $3K in Q3 2018.
341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Institutional & Family Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.